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Background: High interstitial fluid pressure (IFP) in the primary tumor is associated with poor disease-free survival
in locally advanced cervical carcinoma. A noninvasive assay is needed to identify cervical cancer patients with
highly elevated tumor IFP because these patients may benefit from particularly aggressive treatment. It has been
suggested that dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) with gadolinium
diethylene-triamine penta-acetic acid (Gd-DTPA) as contrast agent may provide useful information on the IFP of
cervical carcinomas. In this preclinical study, we investigated whether DCE-MRI with contrast agents with higher
molecular weights (MW) than Gd-DTPA would be superior to Gd-DTPA-based DCE-MRI.
Methods: CK-160 human cervical carcinoma xenografts were subjected to DCE-MRI with Gd-DTPA (MW of
0.55 kDa) or gadomelitol (MW of 6.5 kDa) as contrast agent before tumor IFP was measured invasively with a Millar
SPC 320 catheter. The DCE-MRI was carried out at a spatial resolution of 0.23 × 0.23 × 2.0 mm3 and a time resolution
of 14 s by using a 1.5-T whole-body scanner and a slotted tube resonator transceiver coil constructed for mice.
Parametric images were derived from the DCE-MRI recordings by using the Tofts iso-directional transport model
and the Patlak uni-directional transport model.
Results: When gadomelitol was used as contrast agent, significant positive correlations were found between the
parameters of both pharmacokinetic models and tumor IFP. On the other hand, significant correlations between
DCE-MRI-derived parameters and IFP could not be detected with Gd-DTPA as contrast agent.
Conclusion: Gadomelitol is a superior contrast agent to Gd-DTPA in DCE-MRI of the IFP of CK-160 cervical
carcinoma xenografts. Clinical studies attempting to develop DCE-MRI-based assays of the IFP of cervical
carcinomas should involve contrast agents with higher MW than Gd-DTPA.
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Clinical investigations have shown that the interstitial fluid
pressure (IFP) is elevated in many tumor types, including
lymphoma, melanoma, breast carcinoma, head and neck
carcinoma, and cervical carcinoma [1,2]. In squamous cell
carcinoma of the uterine cervix, for example, IFP values
up to ~50 mmHg have been measured in untreated
tumors, whereas most normal tissues show IFP values
ranging from −3 to +3 mmHg [3-5]. The mechanisms* Correspondence: einar.k.rofstad@rr-research.no
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distribution, and reproduction in any mediumleading to interstitial hypertension in malignant tissues
have been studied extensively in experimental tumors [1].
These studies have shown that elevated IFP is a conse-
quence of severe microvascular, lymphatic, and interstitial
abnormalities. Tumors develop interstitial hypertension
because they show high resistance to blood flow, low re-
sistance to transcapillary fluid flow, and impaired lymph-
atic drainage [6]. The microvascular hydrostatic pressure
is the principal driving force for the elevated IFP of malig-
nant tissues [7]. Fluid is forced from the microvasculature
into the interstitium where it accumulates, distends the
extracellular matrix, and causes interstitial hypertension.
Differences in IFP among tumors result primarily fromtral Ltd. This is an Open Access article distributed under the terms of the
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ences in the architecture of the microvascular network
and from differences in transcapillary fluid flow caused
by differences in the permeability of the vessel walls
[1,6].
A large prospective study of the association between
tumor IFP and outcome of treatment has been carried out
in patients with locally advanced cervical carcinoma at
Princess Margaret Hospital in Toronto [8,9]. The patients
were given radiation therapy without chemotherapy, and
IFP and oxygen tension were measured in the primary
tumor prior to treatment. The study showed that high IFP
was associated with poor disease-free survival independent
of conventional prognostic factors, such as tumor size,
stage, and lymph node status. Moreover, patients with
tumors with high IFP had an increased probability of
developing recurrences both locally within the irradiated
pelvic region and at distant nonirradiated sites. The inde-
pendent prognostic effect of IFP for recurrence and sur-
vival was strong, whereas the independent prognostic
effect of tumor hypoxia was of borderline significance
and was limited to patients without nodal metastases [9].
The main findings reported by the Toronto group have
been confirmed in a smaller prospective study of cervical
carcinoma patients treated with radiation therapy at
Chungnam National University Hospital in Daejeon [10].
Taken together, these studies suggest that cervical carcin-
oma patients with highly elevated tumor IFP may benefit
from particularly aggressive treatment.
Tumor IFP was measured with the wick-in-needle tech-
nique in these studies [8-10]. This is a highly invasive
technique that requires insertion of a fluid-filled 0.5 − 1.0-
mm-thick steel needle into the tumor tissue [7]. Multiple
measurements with the wick-in-needle technique may
lead to erronous IFP readings because of tissue damage
and interstitial fluid leakage from the needle insertion sites
and, consequently, a noninvasive assay for assessing IFP in
cervical carcinoma is highly warranted [1,11]. The possi-
bility that dynamic contrast-enhanced magnetic resonance
imaging (DCE-MRI) with gadolinium diethylene-triamine
penta-acetic acid (Gd-DTPA) as contrast agent may pro-
vide information on the IFP of cervical carcinomas has
been investigated by Haider et al. [12]. Thirty-two un-
treated patients were subjected to DCE-MRI, and signifi-
cant correlations were found between DCE-MRI-derived
parameters and tumor IFP. However, the correlations
were too weak to be clinically useful, perhaps because the
DCE-MRI was not optimized with the purpose of meas-
uring IFP.
DCE-MRI is an attractive strategy for developing a non-
invasive assay of the IFP of tumors because the uptake of
MR contrast agents in malignant tissues is influenced sig-
nificantly by some of the microvascular parameters that
are decisive for the magnitude of the IFP (i.e., tumor bloodperfusion and vessel wall permeability). The molecular
weight of a contrast agent decides whether the uptake
is determined primarily by the blood perfusion or pri-
marily by the vessel wall permeability. The uptake of
low-molecular-weight contrast agents like Gd-DTPA is
governed by the blood perfusion, and with increasing
molecular weight, the uptake becomes increasingly more
dependent on vessel wall permeability [13,14]. Because the
IFP of cervical carcinomas may be influenced significantly
by the permeability of the vessel walls [3,6], Gd-DTPA
may not be the optimal contrast agent for assessing IFP in
cervical cancer, a possibility that was investigated in the
present preclinical study. We hypothesized that DCE-MRI
with contrast agents with higher molecular weights than
Gd-DTPA would provide better measures of tumor IFP
than Gd-DTPA-based DCE-MRI. To test this hypothesis,
human cervical carcinoma xenografts were subjected to
DCE-MRI with Gd-DTPA or gadomelitol as contrast
agent before tumor IFP was measured invasively. Gado-
melitol is an intermediate-sized contrast agent that shows
significant uptake in malignant tissues [15].Methods
Tumor models
CK-160 human cervical carcinoma xenografts growing in
adult female BALB/c nu/nu mice were used as tumor
models [16]. Tumors were initiated from cells cultured in
RPMI-1640 (25 mmol/L HEPES and L-glutamine) medium
supplemented with 13% bovine calf serum, 250 mg/L peni-
cillin, and 50 mg/L streptomycin. Approximately 5.0 × 105
cells in 10 μL of Hanks’ balanced salt solution were inocu-
lated in the gastrocnemius muscle. Tumors with volumes
of 100–800 mm3 were included in the study. DCE-MRI
and IFP measurements were carried out with mice
anesthetized with fentanyl citrate (0.63 mg/kg), fluanisone
(20 mg/kg), and midazolam (10 mg/kg). Animal care and
experimental procedures were in accordance with the
Interdisciplinary Principles and Guidelines for the Use of
Animals in Research, Marketing, and Education (New
York Academy of Sciences, New York, NY).Contrast agents
Two contrast agents were evaluated: Gd-DTPA (MagnevistW;
Schering, Berlin, Germany) with a molecular weight of
0.55 kDa and gadomelitol (VistaremW; Guerbet, Roissy,
France) with a molecular weight of 6.5 kDa. The contrast
agents were diluted in 0.9% saline to a final concentration
of 60 mM (Gd-DTPA) or 7.0 mM (gadomelitol) and were
administered in the tail vein in a bolus dose of 5.0 mL/kg.
The administration was carried out after the mice had
been positioned in the MR scanner by using a 24 G neo-
flon connected to a syringe by a polyethylene tubing.
Figure 1 DCE-MRI data for CK-160 cervical carcinoma xenografts
imaged with Gd-DTPA as contrast agent. (A) Gd-DTPA
concentration versus time for three representative single voxels of a
tumor. The curves were fitted to the data by using the Tofts
pharmacokinetic model. (B) The parametric images of Ktrans and ve and
the corresponding Ktrans and ve frequency distributions of a
representative tumor.
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DCE-MRI was carried out as described earlier [17].
Briefly, T1-weighted images (TR = 200 ms, TE = 3.5 ms,
and αT1 = 80°) were recorded at a spatial resolution of
0.23 × 0.23 × 2.0 mm3 and a time resolution of 14 s by
using a 1.5-T whole-body scanner (Signa; General Elec-
tric, Milwaukee, WI) and a slotted tube resonator trans-
ceiver coil constructed for mice. The coil was insulated
with styrofoam to prevent excessive heat loss from the
mice. The body core temperature of the mice was kept
at 37 − 38°C during imaging by using a thermostatically
regulated heating pad. Two calibration tubes, one with
0.5 mM (Gd-DTPA) or 0.06 mM (gadomelitol) of con-
trast agent in 0.9% saline and the other with 0.9% saline
only, were placed adjacent to the mice in the coil. The
tumors were imaged axially in a single section through
the center by using an image matrix of 256 × 128, a
field of view of 6 × 3 cm2, and one excitation. Two
proton density images (TR = 900 ms, TE = 3.5 ms, and
αPD = 20°) and two T1-weighted images were acquired
before the contrast was administered, and T1-weighted
images were recorded for 15 min after the contrast ad-
ministration. Contrast agent concentrations were calcu-
lated from signal intensities by using the method of
Hittmair et al. [18]. The DCE-MRI series were analyzed
on a voxel-by-voxel basis by using the iso-directional
transport model of Tofts et al. [14] and the uni-
directional transport model of Patlak et al. [19].
According to the Tofts model,





Ca tð Þ:e Ktrans: Ttð Þ=veð Þdt
þ VToftsb :Ca Tð Þ
where Ct(T) is the concentration of contrast agent in the
tissue at time T, Ca(T) is the arterial input function, Hct
is the hematocrit, Ktrans is the volume transfer constant
of the contrast agent, ve is the fractional distribution vol-
ume of the contrast agent in the tissue, and Vb
Tofts is the
fractional blood volume of the tissue [14]. Parametric
images of Ktrans,ve, and Vb
Tofts were determined from the
best curve fits to plots of Ct versus T.
The uni-directional transport model of Patlak et al.
[19] is based on the assumption that the transfer of con-
trast agent from blood to tissue is irreversible and obeys
first-order kinetics. According to this model,
Ct Tð Þ







Ca Tð Þ þ V
Patlak
b
where Ct(T) is the tissue concentration of contrast agent
at time T, Ca(T) is the concentration of contrast agent inthe blood at time T, Hct is the hematocrit, Ki is the influx
constant of the contrast agent from the blood to the tissue,
and Vb
Patlak is the fractional blood volume of the tissue
[19]. Plots of Ct(T)/Ca(T) versus
R
Ca(t)dt/Ca(T) are linear
when the assumptions of the model are fulfilled. Para-
metric images of Ki and Vb
Patlak were determined by fitting
linear curves to the data acquired 1–6 min after the con-
trast administration.
By analyzing blood samples [20,21], the arterial input
functions were found to be double exponential functions
Ca Tð Þ ¼ A:eB:T þ C:eD:T
with constants: A = 2.55 mM, B = 0.080 s−1, C = 1.20 mM,
and D = 0.0010 s−1 (Gd-DTPA) and A = 0.086 mM,
B = 0.043 s−1, C = 0.363 mM, and D = 0.0025 s−1
(gadomelitol).
Figure 2 DCE-MRI and IFP data for CK-160 cervical carcinoma
xenografts imaged with Gd-DTPA as contrast agent. (A) IFP
versus tumor volume. (B) Median Ktrans versus IFP. (C) Median ve
versus IFP. The points represent single tumors.
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IFP was measured in the center of the tumors with a
Millar SPC 320 catheter equipped with a 2 F Mikro-Tip
transducer (Millar Instruments, Houston, TX) [22]. The
catheter was connected to a computer via a Millar TC-510
control unit and a model 13-66150-50 preamplifier (Gould
Instruments, Cleveland, OH). Data acquisition was carried
out by using LabVIEW software (National Instruments,
Austin, TX).Statistical analysis
Curves were fitted to data by regression analysis. The
Pearson product moment correlation test was used to
search for correlations between parameters. Probability
values (P) and correlation coefficients (R2) were calculated
by using SigmaStat software (SPSS Science, Chicago, IL).
A significance criterion of P < 0.05 was used.Results
DCE-MRI with Gd-DTPA as contrast agent was carried
out on eighteen tumors. The plots of Ct(T)/Ca(T) versusR
Ca(t)dt/Ca(T) were not linear, most likely because the
assumptions of the uni-directional transport model of
Patlak were not fulfilled and, consequently, reliable
images of Ki and Vb
Patlak could not be established for
Gd-DTPA. In contrast, the Tofts model gave good curve
fits to the plots of Ct versus T, but the uncertainty in the
calculations of Vb
Tofts were too large that reliable values for
this parameter could be obtained, probably because the
temporal resolution of the DCE-MRI was not sufficiently
high. The curve fitting with the Tofts model was therefore
carried out by ignoring the signal from the tumor blood
plasma (i.e., Vb
Tofts was set to zero). The quality of the
curve fitting is illustrated in Figure 1A, which refers to
three representative single voxels differing in the rates of
uptake and wash-out of Gd-DTPA. Parametric images of
Ktrans and ve and the corresponding K
trans and ve frequency
distributions of a representative tumor are presented in
Figure 1B. In general, the tumors were highly heteroge-
neous in Ktrans with the highest values in the periphery
and the lowest values in the center. The intratumor het-
erogeneity in ve was also substantial, but did not follow a
fixed pattern (i.e., low and high values were seen in the
center as well as in the periphery of the tumors).
IFP was measured immediately after the DCE-MRI
and was found to vary among the tumors from 6.5 to
45 mmHg. There was no correlation between IFP and
tumor volume (Figure 2A). Moreover, correlations between
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Figure 2, which shows plots of median Ktrans (Figure 2B)
and median ve (Figure 2C) versus IFP.
Fifteen tumors were subjected to DCE-MRI with gado-
melitol as contrast agent. Parametric images of Ktrans, ve,
Vb
Tofts, Ki, and Vb
Patlak and the corresponding Ktrans, ve,
Vb
Tofts, Ki, and Vb
Patlak frequency distributions of a repre-
sentative tumor are presented in Figure 3A and 3B. The
tumors were heterogeneous in all parameters. In general,
the Ktrans images were similar to the Ki images and the
Vb
Tofts images were similar to the Vb
Patlak images. Good curve
fits were obtained with both pharmacokinetic models.
Examples are presented in Figure 3, which refers to three
representative single voxels and shows the experimental
data and the best curve fits obtained with the Tofts model
(Figure 3C) and the Patlak model (Figure 3D).
As indicated by the images in Figure 3A, the para-
meters derived from the pharmacokinetic analyses were
correlated with each other. This is illustrated in Figure 4,
which shows plots of median Ktrans versus median Vb
Tofts
(Figure 4A; P < 0.0001 and R2 = 0.72), median Ki versus
median Vb
Patlak (Figure 4B; P = 0.0001 and R2 = 0.69),
median Ki versus median K
trans (Figure 4C; P < 0.0001
and R2 = 0.96), and median Vb
Patlak versus median Vb
Tofts
(Figure 4D; P < 0.0001 and R2 = 0.95).
Tumor IFP was measured immediately after the DCE-
MRI also in this experiment and, again, there was no
correlation between IFP and tumor volume (Figure 5A).
Moreover, there was no correlation between median ve
and IFP (Figure 5B). However, significant positive cor-
relations were found between median Ktrans and IFP
(Figure 5C; P = 0.0002 and R2 = 0.66), median Ki and IFP
(Figure 5D; P = 0.0008 and R2 = 0.59), median Vb
Tofts and
IFP (Figure 5E; P = 0.0001 and R2 = 0.70), and median
Vb
Patlak and IFP (Figure 5F; P < 0.0001 and R2 = 0.72).
Discussion
Cervical cancer patients with primary tumors with high
IFP have a poor prognosis and may benefit from aggres-
sive treatment, implying that a noninvasive method for
assessing IFP in cervical carcinomas is needed [8-10].
The potential usefulness of DCE-MRI with Gd-DTPA or
gadomelitol as contrast agent was evaluated in this pre-
clinical study. Significant correlations between DCE-MRI-
derived parameters and IFP were found for gadomelitol,
whereas significant correlations could not be detected for
Gd-DTPA.
CK-160 human cervical carcinoma xenografts were used
as experimental tumor models. This tumor line was estab-
lished from a pelvic lymph node metastasis of a 65-year-
old woman with a well-differentiated (histological grade I)
keratinizing primary tumor. The histological appearance
of CK-160 xenografts is similar to that of the donor
patient’s tumor, and there is evidence that the metastaticpattern and radiation sensitivity of the donor patient’s
tumor are retained after xenotransplantation [16]. The
physiological microenvironment differs substantially among
individual CK-160 xenografts, and the intertumor hetero-
geneity in several pathophysiological parameters is similar
to that reported for cervical carcinomas in humans [16,23].
Thus, IFP values ranging from 6.5 to 45 mmHg were mea-
sured in this work, which is comparable to the IFP values
of up to ~50 mmHg that have been recorded in untreated
tumors in cervical cancer patients [3-5,8-10]. Elevated IFP
in tumors is partly a consequence of abnormalities in the
microvascular network, and the architecture and function
of the microvascular network may differ substantially
among individual tumors of the same experimental line
as a consequence of stochastic processes influencing tumor
angiogenesis shortly after transplantation and during tumor
growth. In CK-160 tumors as well as in tumors of several
other experimental lines, these stochastic processes result
in an intertumor heterogeneity in IFP similar to that
observed in tumors in man [1,7,11,16]. Consequently,
tumors of the CK-160 cervical carcinoma line should be
excellent preclinical models for studying the question
addressed in the present work.
The DCE-MRI was carried out at 1.5 T at a spatial reso-
lution of 0.23 × 0.23 × 2.0 mm3 and a time resolution of
14 s. By subjecting the same tumors to Gd-DTPA-based
DCE-MRI twice, we have shown that our DCE-MRI method
produces highly reproducible Ktrans and ve images [20].
Moreover, Monte Carlo analysis has revealed that the
signal-to-noise ratio is sufficiently high that the Ktrans and
ve images are not influenced significantly by noise [24], a
finding that was confirmed to be valid also in this work.
However, our DCE-MRI method has some limitations.
Thus, only a single axial slice through the tumor center
was scanned, and the influence of any interanimal vari-
ation in the arterial input function was ignored. However,
as discussed in detail previously, the benefit of consid-
ering these factors is small in standardized preclinical
studies [17]. The strengths and weaknesses of our DCE-
MRI procedure have been reviewed thoroughly elsewhere
[17,20,24].
The DCE-MRI series were analyzed with the Tofts iso-
directional transport model [14] and the Patlak uni-
directional transport model [19]. The main difference
between these models is that any transfer of contrast
agent from the interstitium to the blood is taken into
consideration in the Tofts model whereas the Patlak
model assumes irreversible transfer of contrast from the
blood to the interstitial space. By neglecting the redistri-
bution rate constant in the Tofts model, the general




The Gd-DTPA data could not be analyzed reliably
with the Patlak model because the condition of uni-
Figure 3 (See legend on next page.)
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Figure 3 DCE-MRI data for CK-160 cervical carcinoma xenografts imaged with gadomelitol as contrast agent. (A) The parametric images
of Ktrans, ve, Vb
Tofts, Ki, and Vb
Patlak of a representative tumor. (B) The Ktrans, ve, Vb
Tofts, Ki, and Vb
Patlak frequency distributions of the same tumor. (C)
Gadomelitol concentration versus time for three representative single voxels of the same tumor. The curves were fitted to the data by using the
Tofts pharmacokinetic model. (D) Ct(T)/Ca(T) versus
R
Ca(t)dt/Ca(T) for the same three voxels. The curves were fitted to the data by using the Patlak
pharmacokinetic model.
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(T)/Ca(T) versus
R
Ca(t)dt/Ca(T) were not linear). The Tofts
model gave good fits to the Gd-DTPA data, but the uptake
of Gd-DTPA was too fast relative to the temporal reso-
lution of the DCE-MRI to obtain reliable values for Vb
Tofts.
The analysis of the Gd-DTPA data with the Tofts model
was therefore carried out by setting Vb
Tofts equal to zero, a
simplification that has been shown to have insignificant
consequences for the numerical values of Ktrans and ve in
tumors with blood volume fractions of less than 5% [13].
According to the gadomelitol data in Figure 5, the blood
volume fraction is less than 3% in CK-160 tumors. Conse-
quently, it is unlikely that there were correlations between
Ktrans and IFP and/or ve and IFP that were not detected
because of inadequate pharmacokinetic analysis of the
Gd-DTPA data.
The gadomelitol data on the other hand could be ana-
lyzed reliably with both pharmacokinetic models, and the
results did not differ significantly between the models.
Thus, the Ktrans images were similar to the Ki images andFigure 4 DCE-MRI data for CK-160 cervical carcinoma xenografts imag
median Vb
Tofts. (B) Median Ki versus median Vb
Patlak. (C) Median Ki versus medi
single tumors. The curves were fitted to the data by linear regression analythe Vb
Tofts images were similar to the Vb
Patlak images. Fur-
thermore, significant correlations were found between
median Ktrans and median Ki and between median Vb
Tofts
and median Vb
Patlak. However, median Ki was somewhat
lower than median Ktrans and median Vb
Patlak was somewhat
higher than median Vb
Tofts, probably because the condition
of uni-directional transport was not fulfilled completely.
Vb
Tofts is assumed to represent tumor blood volume
fraction, whereas the physiological interpretation of Ktrans
is more complex because Ktrans is influenced by the blood
perfusion and the vessel surface area of the imaged tumor
and the vessel wall permeability of the contrast agent [14].
In high-permeability situations where the flow of contrast
across the vessel wall is limited by the blood supply (i.e.,
low-molecular-weight contrast agents and leaky, immature
blood vessels), Ktrans is determined primarily by the tumor
blood perfusion. In low-permeability situations where the
flow of contrast across the vessel wall is limited by the
vessel wall itself (i.e., high-molecular-weight contrast
agents and mature vessels), Ktrans is determined primarilyed with gadomelitol as contrast agent. (A) Median Ktrans versus
an Ktrans. (D) Median Vb
Patlak versus median Vb
Tofts. The points represent
sis.
Figure 5 DCE-MRI and IFP data for CK-160 cervical carcinoma xenografts imaged with gadomelitol as contrast agent. (A) IFP versus
tumor volume. (B) Median ve versus IFP. (C) Median K
trans versus IFP. (D) Median Ki versus IFP. (E) Median Vb
Tofts versus IFP. (F) Median Vb
Patlak versus
IFP. The points represent single tumors. The curves were fitted to the data by linear regression analysis.
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represents vessel wall permeability and S represents vessel
surface area per unit tumor volume. CK-160 tumors have
mature blood vessels embedded in bands of connective
tissue [25], and because the uptake of gadomelitol was
slow compared with that of Gd-DTPA, it is likely that the
Ktrans of gadomelitol was determined mainly by the per-
meability surface area product rather than the blood per-
fusion. Moreover, because strong correlations were found
between Ktrans and Vb
Tofts and between Ki and Vb
Patlak, the
differences in Ktrans and Ki among the individual CK-160
tumors was most likely a consequence of differences in
vessel surface area rather than vessel wall permeability.
Significant correlations were found between the Ktrans,
Ki, Vb
Tofts, and Vb
Patlak of gadomelitol on the one hand andIFP on the other. Although the transcapillary permeability
of gadomelitol appears to be low in CK-160 tumors, the
hydraulic conductivity of the vessel walls may be high.
The differences in IFP among tumors with high vessel
wall hydraulic conductivity are mainly a consequence
of differences in viscous and geometric resistance to
blood flow [1,6]. Several microvascular parameters
may cause high resistance to blood flow in tumor tis-
sues, including small vessel diameters, long vessel
segment lengths, and high vessel tortuosity [26]. In
contrast to small vessel diameters and long vessel
segment lengths, high vessel tortuosity may be asso-
ciated with high vascular fractions in tumors, as
shown for U-25 melanoma xenografts [27]. Conse-
quently, the correlations between Ktrans and IFP, Ki
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Tofts and IFP, and Vb
Patlak and IFP in CK-160
tumors most likely appeared because high vessel tortuosity
resulted in high IFP as well as high blood volume fractions
and large vessel surface areas.
Previously, we have investigated the potential of DCE-
MRI as a method for assessing IFP in tumors by using
orthotopic A-07 melanoma xenografts as experimental
tumor models [21,28]. When Gd-DTPA was used as con-
trast agent, a significant inverse correlation was found
between Ktrans and IFP [28]. With gadomelitol as con-
trast agent, significant postive correlations were found
between Vb
Tofts and IFP and between Vb
Patlak and IFP
[21]. There was no correlation between Ktrans and Vb
Tofts
or Ki and Vb
Patlak in that study and, hence, no correl-
ation between Ktrans and IFP or Ki and IFP. The obser-
vations reported here for CK-160 cervical carcinomas
thus differ substantially from those reported for the A-
07 melanomas. The apparent discrepancies are most
likely a consequence of differences in the microvascular
network and in the quantity and distribution of con-
nective tissue. The fraction of connective tissue is >30%
and the fraction of vessels associated with connective
tissue is ~80% in CK-160 tumors, whereas in A-07
tumors, the fraction of connective tissue is <10% and
the fraction of vessels associated with connective tissue
is ~10% [25]. Moreover, the majority of the microves-
sels in CK-160 cervical carcinomas are surrounded by
broad bands of connective tissue, whereas most micro-
vessels in A-07 melanomas are not separated from the
parenchyma by connective tissue [25]. In fact, because
the transvascular and interstitial transport of MR con-
trast agents is inhibited by connective tissue and the
extent of inhibition is influenced significantly by the
molecular weight of the contrast agent, we expected
that the results from the present study of CK-160
tumors would differ from those of our previous studies
of A-07 tumors, and this expectation was verified to be
valid.
Taken together, our studies of A-07 melanoma xeno-
grafts and CK-160 cervical carcinoma xenografts suggest
that assessment of the IFP of tumors by DCE-MRI may
require different strategies for different histological types
of cancer, depending on the resistance to transcapillary
transport of MR contrast agents. For tumors similar to
the A-07 tumors, which show low resistance to transca-
pillary transport, DCE-MRI parameters related to blood
perfusion (e.g., the Ktrans of low-molecular-weight con-
trast agents like Gd-DTPA) and to blood volume frac-
tion (e.g., the Vb
Tofts and Vb
Patlak of intermediate-sized
contrast agents like gadomelitol) may provide informa-
tion on tumor IFP. For tumors similar to the CK-160
tumors, which show increased resistance to transcapil-
lary transport, information on tumor IFP may be derived
from DCE-MRI parameters related to the permeabilitysurface area product (e.g., the Ktrans, Ki,Vb
Tofts, and Vb
Patlak
of intermediate-sized contrast agents like gadomelitol).
It should be noticed, however, that these suggestions
are based on studies involving only one tumor line with
little connective tissue and only one tumor line with
substantial quantities of connective tissue. This is a sig-
nificant limitation, and further studies involving several
tumor lines of each category are needed before definite
conclusions can be drawn.
It should also be noticed that Haider et al. [12] have
investigated whether DCE-MRI with Gd-DTPA as con-
trast agent may provide information on the IFP of the
primary tumor of patients with cervical cancer. They
found weak but significant inverse correlations between
two Ktrans-related parameters (rktrans and IAUC60m) and
IFP and suggested that rktrans and IAUC60m may be of
value in assessing the IFP and, hence, the clinical behavior
of cervical carcinomas. These observations were not con-
firmed in the present study of CK-160 cervical carcinoma
xenografts. Our study rather suggests that the Ktrans of
Gd-DTPA may not be associated with IFP in cervical
carcinomas and, furthermore, that assessment of IFP in
cervical carcinomas by DCE-MRI may require contrast
agents with higher molecular weights than Gd-DTPA.Conclusions
As opposed to Gd-DTPA based DCE-MRI, DCE-MRI
with gadomelitol as contrast agent may provide informa-
tion on the IFP of cervical carcinoma xenografts. Because
our study involved tumors of a single line only and only
one contrast agent was investigated, further preclinical
studies are needed. These studies should include several
cervical carcinoma xenograft lines and several contrast
agents differing in molecular weight. Furthermore, clinical
attempts to develop a DCE-MRI assay of the IFP of cer-
vical carcinomas should involve medium-sized contrast
agents like gadomelitol.
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